Latest CSL Limited Stories
rIX-FP Regulatory Submissions Now Made in EU and U.S.; Underscores CSL Behring's Legacy of Improving the Care for Patients with Bleeding Disorders KING OF PRUSSIA,
Study Finds Kcentra® is Superior to Plasma in Patients Needing Warfarin Reversal for Urgent Surgical or Invasive Procedures KING OF PRUSSIA, Pa., March 17, 2015 /PRNewswire/ --
Company and Employees Cultivate a Culture of Giving, Including Partnering with Children's Scholarship Fund Philadelphia KING OF PRUSSIA, Pa., March 9, 2015 /PRNewswire/ -- CSL Behring announced
BRAINTREE, Mass. and BOCA RATON, Fla., March 5, 2015 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) and CSL Plasma, Inc. announced today that CSL Plasma, Inc.
CSL Behring Pioneered Donations to WFH Program; Further Underscores Commitment to Providing Global Bleeding Disorders Community with Access to Treatment KING OF PRUSSIA, Pa., Feb.
GIA announces the release of a comprehensive global report on Intravenous Immunoglobulin (IVIg).
CSL Behring Achieves Another Key Milestone in PROLONG-9FP, its Recombinant Factor IX Fusion Protein Development Program; Continues to Advance CSL Behring's Legacy of Improving Patient Well-Being
New Label Supports Individualized Therapy Through Greater Dosing Flexibility From Daily to Once Every Two Weeks (Biweekly); Underscores CSL Behring's Commitment to Improving Patients' Lives
- a slit in a tire to drain away surface water and improve traction.